Moderna Has a Platform and a Boom. Only One of Them Is Still Generating Revenue.

In 2022, Moderna sold $19.3 billion of a single product.² By full-year 2024, total revenue across everything it makes had fallen to $3.2 billion, and the company posted a $3.6 billion net loss.¹ By the third quarter of 2025, quarterly revenue was down to $1.0 billion - a 45% drop year over year - and still falling.³ That is what the end of a boom looks like: not a plateau, but a slide that keeps sliding. The interesting question is not whether the COVID money is gone. It is gone. The question is what Moderna actually owns once it leaves.

The official story is that Moderna was never a vaccine company at all. It was a platform company - a programmable mRNA stack where the next product is just new code loaded into a proven factory. COVID was supposed to be the first printout, not the business. The platform thesis is real, and it is mostly true. But there is a gap between owning a printing press and owning a publishing house, and that gap is where Moderna currently lives.

The platform is real. The catalog is one item long.

Here is the strongest version of Moderna's case, stated fairly. mRNA is genuinely a platform: the manufacturing process barely changes between products, so a validated process for one vaccine is most of the process for the next. The COVID vaccine proved the stack works at planetary scale. And the company sits on $9.5 billion in year-end cash¹ - enough runway to fund a pipeline through years of trials without raising a dollar in panic. That is a serious technology moat, and it would be foolish to wave it away.

Now the gap. A platform earns its name when it produces many products. Moderna's platform has, to date, produced exactly one new commercial product beyond COVID: mRESVIA, its RSV vaccine. Full-year 2024 sales were $25 million.¹ In the third quarter of 2025, mRESVIA sold $2 million.³ Set that against Spikevax's $3.1 billion in 2024¹ and the shape is unmistakable - this is still a one-product company that happens to own a very promising factory. The press release of the platform has been written. The catalog hasn't.

Who actually built the factory

There is a second crack in the standalone-genius story, and it sits in the foundation. The mRNA COVID vaccine was not a purely private invention. NIH's NIAID co-developed mRNA-1273, including the spike-protein stabilization design at the heart of the vaccine, alongside Moderna's scientists.⁵ And the public stake was not symbolic: a peer-reviewed study found U.S. agencies invested a total of $31.9 billion in mRNA vaccine research and procurement from 1985 to March 2022, including $337 million of pre-pandemic R&D.⁴ This matters strategically, not just historically. A moat partly dug with public money is a moat the public can take an interest in - through pricing pressure, licensing claims, and, as we'll see, contract decisions. Moderna's platform is co-invented infrastructure that a private company now meters. That is a strong position. It is not an unencumbered one.

The IP fortress took fire in its own backyard

If the platform's commercial moat is the runway and the pipeline, its legal moat is the patent estate - and that estate is under live attack. In March 2025, the USPTO's Patent Trial and Appeal Board invalidated most claims of two of Moderna's key SARS-CoV mRNA patents, in proceedings brought by the obvious adversaries: BioNTech and Pfizer.⁶ This is the underreported half of the story. The headlines tend to feature Moderna's wins - and there have been wins abroad - but a domestic invalidation of core claims is exactly the kind of result a 'fortress IP' narrative is built to make you forget. Litigation over the broader portfolio continues.⁶ The point is not that Moderna will lose. The point is that the moat is being contested in court, right now, by the only rivals who matter - which means it was never the impassable wall the platform story implied.

Isn't government de-funding the real threat?

The fashionable bear case in 2025 was political: HHS/BARDA wound down mRNA contracts - 22 of them, totaling around $500 million - and terminated Moderna's H5N1 pandemic flu deal.⁸ Read fast, this looks like the government pulling the rug. Read carefully, it doesn't. Moderna confirmed it has no other active BARDA collaborations beyond the already-disclosed H5N1 cancellation;⁸ the broader wind-down falls mostly on smaller players and academic labs, not Moderna's commercial pipeline. So the honest counter to my own thesis is that the de-funding scare is mostly noise - Moderna's real vulnerability isn't a lost contract, it's the empty space on the shelf. And the empty space has a plausible filler: mRNA-4157, its personalized cancer vaccine with Merck, which met its primary endpoint in the Phase 2b KEYNOTE-942 melanoma trial and entered Phase 3 in early 2025, with regulatory submissions anticipated in 2026.⁷ If that reads out, the catalog stops being one item long. Notice the tense, though. If. The bull case rests entirely on trials that have not yet finished.

So does the mRNA platform hold after the boom? Mostly yes - and that 'mostly' is the whole story. The technology is validated, the cash buys years, and the science behind a programmable medicine stack is no longer in doubt. But a moat you can describe and a moat that is generating revenue are different objects, and Moderna currently owns the first while waiting on the second. The factory is built, paid down to $9.5 billion in reserves, partly with public money, defended by patents now contested in court. It can print almost anything. The only thing it has not yet done is print a second product anyone is buying. The platform is real. Its catalog is a promissory note - and 2026 is when it comes due.